Cargando…

ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report

Epithelioid inflammatory myofibroblastic sarcoma (EIMS), a specific subtype of inflammatory myofibroblastic tumors (IMT), is a relatively rare malignant mesenchymal tumor with clinical features of positive anaplastic lymphoma kinase (ALK), high invasiveness, treatment resistance and poor prognosis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xiaojing, Li, Hong, Peng, Ke, Yu, Yiyi, Chen, Lingli, Fang, Yong, Sun, Yihong, Hou, Yingyong, Liu, Tianshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341694/ https://www.ncbi.nlm.nih.gov/pubmed/30675302 http://dx.doi.org/10.3892/ol.2018.9865

Ejemplares similares

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report
por: Aminimoghaddam, Soheila, et al.
Publicado: (2023)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma
por: Jiang, Quan, et al.
Publicado: (2017)

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma
por: Fordham, Ashleigh M., et al.
Publicado: (2020)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
por: Badran, Ahmed, et al.
Publicado: (2023)

Epithelioid inflammatory myofibroblastic sarcoma: the youngest case reported
por: Batool, Sajida, et al.
Publicado: (2021)

Pericardial Epithelioid Inflammatory Myofibroblastic Sarcoma: An Atypical Presentation
por: Azad, Mazieyar, et al.
Publicado: (2022)

A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation
por: Trabelsi-Grati, Olfa, et al.
Publicado: (2020)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report
por: Wang, Zhan, et al.
Publicado: (2022)

Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report
por: Chennouf, Anas, et al.
Publicado: (2017)

Crizotinib and Surgery for Long-Term Disease Control in Children and Adolescents With ALK-Positive Inflammatory Myofibroblastic Tumors
por: Trahair, Toby, et al.
Publicado: (2019)

Epithelioid inflammatory myofibroblastic sarcoma: a case report and brief literature review
por: Dou, Weidong, et al.
Publicado: (2023)

Epithelioid Inflammatory Myofibroblastic Sarcoma Presenting as Gastrointestinal Bleed: Case Report and Literature Review
por: Giannaki, Alexandra, et al.
Publicado: (2020)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature
por: Fu, Xinge, et al.
Publicado: (2015)

Primary pulmonary epithelioid inflammatory myofibroblastic sarcoma: a rare entity and a literature review
por: Singh, Priyanka, et al.
Publicado: (2022)

Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report
por: Zhang, Peng, et al.
Publicado: (2023)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib
por: Khalil, Sumaira, et al.
Publicado: (2020)

miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 Family
por: Xie, Zijun, et al.
Publicado: (2022)

Incomplete Intestinal Obstruction Caused by a Rare Epithelioid Inflammatory Myofibroblastic Sarcoma of the Colon: A Case Report
por: Bai, Yanjun, et al.
Publicado: (2015)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Epithelioid inflammatory myofibroblastic sarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic analysis of five additional cases and review of the literature
por: Yu, Lin, et al.
Publicado: (2016)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity
por: Chuang, Yu-Chung, et al.
Publicado: (2019)

ALK negative inflammatory myofibroblastic tumor of the orbit: A masquerading entity
por: Dutta, Vibha, et al.
Publicado: (2014)

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma
por: Sandoval, Letícia, et al.
Publicado: (2019)

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion
por: Li, XiaoQing, et al.
Publicado: (2023)

Epithelioid sarcoma of the orbit
por: Alkatan, Hind M., et al.
Publicado: (2011)

Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
por: Yuan, Cai, et al.
Publicado: (2017)

Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment
por: Chen, Weijie, et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

An Unusual Case of Systemic Inflammatory Myofibroblastic Tumor with Successful Treatment with ALK-Inhibitor
por: Jacob, Sanjivini V., et al.
Publicado: (2014)

Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells
por: Boulos, Joelle C., et al.
Publicado: (2021)

ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report
por: Qiu, Ye, et al.
Publicado: (2019)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
por: Zhang, Xiangming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iap9c99dm2ef4gargnb20v82ol